OBJECTIVE -The purpose of this study was to elucidate whether serum adiponectin is associated with progression of diabetic nephropathy in type 1 diabetic patients.
A diponectin, a hormone that is secreted exclusively from adipocytes (1), has consistently been shown to be higher in patients with renal disease than in healthy subjects (2,3). Serum adiponectin concentrations are also increased in type 1 diabetes (4) and especially in patients who have diabetic nephropathy (5, 6) .
The mechanisms responsible for the increase are still unclear. However, high plasma adiponectin concentrations decrease after renal transplantation, suggesting that renal insufficiency may either have an effect on the clearance of adiponectin and/or have a stimulatory effect on adiponectin production (7) . In a recent study in patients with type 2 diabetes and overt diabetic nephropathy, the increase in serum adiponectin was suggested to reflect enhanced production of adiponectin in the adipose tissue rather than a reduced clearance of adiponectin by the kidneys (8) .
It could be speculated that adiponectin itself may play a compensatory role in mitigating the disease burden induced by renal disease via its antiatherogenic and anti-inflammatory properties (9) . Supportive of this view, high circulating adiponectin concentrations have been associated with a better prognosis not only in patients with end-stage renal disease (ESRD) and cardiovascular disease (CVD) (10) , but also in patients with mild to moderately impaired kidney function and CVD (11) . Interestingly, high adiponectin concentrations were associated with the occurrence of microalbuminuria in a 6-year follow-up study in 126 patients with type 1 diabetes and normoalbuminuria at baseline (12) . This observation suggests that adiponectin may in fact promote development and progression of diabetic nephropathy despite a potential protective effect regarding CVD. Therefore, this study was performed to elucidate whether adiponectin plays a role in the development and progression of diabetic nephropathy in patients with type 1 diabetes.
RESEARCH DESIGN AND
METHODS -This study is part of the ongoing prospective Finnish Diabetic Nephropathy Study (FinnDiane), which is a nationwide, comprehensive multicenter study that started in 1998 with the aim of identifying genetic and environmental risk factors for diabetic nephropathy in patients with type 1 diabetes. At baseline, patients underwent a thorough clinical investigation that took place in conjunction with a regular visit to the attending physician. Two different approaches complementing each other were used for follow up of the patients. First, for all patients included in the present analysis, the medical files were reviewed, and any changes in renal status or the occurrence of cardiovascular events was verified. Second, all patients were reexamined at their local medical center according to the same protocol as at the baseline visit.
A total of 1,330 patients with type 1 diabetes were included in the present study. The mean Ϯ SD follow-up time was 5.0 Ϯ 2.2 years. Based on their urinary albumin excretion rate (AER) in three consecutive overnight or 24-h urine collections, 818 patients had a normal AER (AER Ͻ20 g/min or Ͻ30 mg/24 h), 216 patients had microalbuminuria (20 g/min Յ AER Ͻ 200 g/min or 30 mg/24 h Յ AER Ͻ 300 mg/24 h), and 296 patients had macroalbuminuria (AER Ն200 g/min or AER Ն300 mg/24 h). Patients with ESRD, defined as patients undergoing dialysis or having received a kidney transplant, were not included in the analysis.
Progression of renal disease was defined as follows: all data on AER obtained between baseline and the follow-up visit were reviewed, and based on the result in two of the last three consecutive urine collections, the renal status of the patients was determined using the same cutoff values as in the baseline examination. Progression was defined as a change from one level to a higher level of AER or the development of ESRD. Patients without progression of renal disease were classified as nonprogressors. Type 1 diabetes was defined as an onset of diabetes before the age of 35 years and permanent insulin treatment initiated within 1 year of diagnosis. The study also included healthy control subjects (n ϭ 204) to be able to compare adiponectin concentrations between healthy subjects and patients with type 1 diabetes.
The ethics committees of all participating centers approved the study protocol. Written informed consent was obtained from each patient, and the study was performed in accordance with the Declaration of Helsinki as revised in the year 2000.
At the regular patient visits, data on medication and diabetic complications were registered using a standardized questionnaire, which was completed by the patient's attending physician and based on medical files and the clinical evaluation. Blood pressure was measured twice in the sitting position with a mercury sphygmomanometer after a 10-min rest and the average of these measurements were used in the analysis. Height, weight, and waist-to-hip ratio were recorded, and blood was drawn for the measurements of A1C, lipids, creatinine, and adiponectin. Estimated glucose disposal rate was calculated as described earlier and was used as a measure of insulin sensitivity (13) .
A1C was determined by standardized assays at each center. Serum lipid and lipo- Data are means Ϯ SD (n).
protein concentrations were measured at the research laboratory of the Helsinki University Central Hospital, Division of Cardiology, Helsinki, Finland, by automated enzymatic methods using the Cobas Mira analyzer (Hoffmann-La Roche, Basel, Switzerland). Serum creatinine was assessed by enzymatic methods at a central laboratory. Urinary AER was determined by radioimmunoassay (Pharmacia, Uppsala, Sweden) or immunoturbidimetry. The estimated glomerular filtration rate (eGFR) was determined with the Cockroft-Gault formula (14) . Serum adiponectin was determined by a timeresolved immunofluorometric assay (15) .
Statistical analysis
Data are expressed as means Ϯ SD for normally distributed values and as median (range) for non-normally distributed values. Differences between groups for normally distributed variables were tested using ANOVA, and for nonparametric data the Kruskal-Wallis test was used. Categorical variables were analyzed with a 2 test. Risk factors for the progression of diabetic nephropathy were assessed using Cox regression analysis. All calculations were performed with SPSS 12.01 (SPSS, Chicago, IL). P Ͻ 0.05 was considered statistically significant. Table 1 . Patients with macroalbuminuria were older and had a longer duration of diabetes than patients in the other groups. Glycemic control was worst in patients with macroalbuminuria. Serum adiponectin concentrations were similar in patients with normoalbuminuria and microalbuminuria but higher in patients with macroalbuminuria (P Ͻ 0.001). Healthy control subjects had, as expected, significantly lower adiponectin serum concentrations (9.93 Ϯ 4.52 mg/l) than patients with type 1 diabetes and normoalbuminuria (12.1 Ϯ 5.8 mg/l, P Ͻ 0.001) or microalbuminuria (12.3 Ϯ 6.2 mg/l, P Ͻ 0.001).
RESULTS -Clinical characteristics of the patients are shown in
Seventy-three of 818 patients with normoalbuminuria progressed to microalbuminuria, 37 of 216 progressed from microalbuminuria to macroalbuminuria, and 83 of 296 progressed from macroalbuminuria to ESRD. In patients with normoalbuminuria or microalbuminuria, there were no differences in the baseline adiponectin concentrations between progressors or nonprogressors (Table 2) , not even when men and women were analyzed separately (data not shown). However, in the macroalbuminuria group, progressors had significantly higher serum adiponectin concentrations compared with nonprogressors (Table 2 ).
In patients with macroalbuminuria, systolic blood pressure, insulin dose, A1C, cholesterol, triglycerides, creatinine, AER, and eGFR were all associated with progression from macroalbuminuria to ESRD in univariate analyses (Table 3) . When systolic blood pressure, insulin dose, A1C, cholesterol, triglycerides, eGFR, and adiponectin were inserted in a Cox regression analysis, A1C, triglycerides, eGFR, and adiponectin were significantly associated with progression from macroalbuminuria to ESRD (Table 4) .
CONCLUSIONS -The major new
finding of the present study is the demonstration that an increased serum concentration of adiponectin at baseline is prognostic for the progression from overt diabetic nephropathy to ESRD in patients with type 1 diabetes. However, we could not observe any differences in the serum adiponectin concentrations in patients with normoalbuminuria or microalbuminuria irrespective of whether or not they were progressors.
These data are in contrast to results from a previously published study; however, that study included only 126 patients with type 1 diabetes (12) . It is notable that we studied a substantially larger patient population, which may explain the observed difference. Furthermore, our patients with normoalbuminuria were younger and had better glycemic control and higher BMI. Notably, our observation is also in contrast to the observation made in the Modification of Diet in Renal Disease (MDRD) study, in which the investigators could not find an association between adiponectin and the progression of kidney disease, even if they included patients with moderate to advanced kidney disease (16) . A plausible explanation for this discrepancy might be our larger patient population and the fact that the MDRD study included only 42 patients with diabetes, and none of them had type 1 diabetes.
As expected, most of our patients with type 1 diabetes and diabetic nephropathy were treated with an ACE inhibitor or an ARB, agents that have been shown to increase serum adiponectin in nondiabetic patients with hypertension (17) . However, we could not observe any differences in adiponectin concentrations whether or not the patients were taking ACE inhibitors, an observation that is in line what has been shown recently in a study of patients with type 2 diabetes and hypertension (18) . In patients with type 1 diabetes, treatment with an ARB was shown to increase the adiponectin concentration in a small-scale study (19) , but in two other later studies, there was no effect of an ACE inhibitor or an ARB (15, 20) . The great majority of the patients in the macroalbuminuric group in our study were receiving ACE inhibitor treatment and only 25 patients were receiving ARB treatment.
The reason that adiponectin may be prognostic for the progression from macroalbuminuria to ESRD in patients with type 1 diabetes is not yet known. However, it may be a mechanism by which the body compensates for the demands created by the diabetic milieu. Importantly, glycosylation represents one of the major post-translational modifications of adiponectin, which, together with hydroxylation, is supposed to be critical for the three-dimensional structure of the biologically active adiponectin molecule (21) (22) (23) . Notably, even a relatively short period of high plasma glucose has been reported to lead to an increase in the production of the biologically highly active high-molecular weight adiponectin (23) . Whether this mechanism is still present in chronic hyperglycemia in type 1 diabetic patients with macroalbuminuria is unknown; however, in support of this hypothesis, the present patients with type 1 diabetes and macroalbuminuria had worse glycemic control than patients with normo-or microalbuminuria. Further, A1C and adiponectin were both associated with the progression of diabetic nephropathy. In addition, renal insufficiency per se has been suggested to trigger an increase in adiponectin concentrations. According to a study in patients with type 2 diabetes and overt diabetic nephropathy, enhanced production of adiponectin has been suggested to be a stronger determinant of serum adiponectin concentrations than a reduction in the clearance of adiponectin by the kidneys (8) . It is of note that in our study adiponectin was an independent predictor of progression from macroalbuminuria to ESRD irrespective of patients' eGFRs.
In summary, increased adiponectin concentration is prognostic for the progression from overt diabetic nephropathy to ESRD in patients with type 1 diabetes.
